{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:41:45Z","timestamp":1761986505822},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/igo\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Live-attenuated influenza vaccines (LAIVs) are not licensed in children younger than 2 years of age because of a wheezing safety signal that has not been fully elucidated. In 2000, the Kaiser Permanente Vaccine Study Center conducted a placebo-controlled randomized clinical trial (RCT) of LAIV in children. As many of these children were still enrolled in Kaiser Permanente in 2014, we could assess the possible long-term association between LAIV and subsequent asthma diagnosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We identified all children who were originally enrolled into the LAIV RCT at younger than 3 years of age. We followed up subjects until disenrollment from the health plan, a first diagnosis of asthma, or through the end of the study period in 2014. Asthma was defined by a first International Classification of Diseases, 9th revision, Clinical Modification code (493.*) assigned at an outpatient or emergency department encounter. We performed a survival analysis of time to first asthma diagnosis among children receiving LAIV or placebo with a Cox proportional hazards model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>We identified 1151 children in the original RCT who were 12 through 35 months of age at the time of enrollment and who had received 2 doses of LAIV or placebo. A total of 767 (66.7%) RCT participants were still Kaiser Permanente Northern California members in 2014. There was no evidence of differential dropout by treatment group. The hazard ratio for new-onset asthma for LAIV recipients compared with placebo was 1.1 (95% confidence interval: 0.88\u20131.41; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.38).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>We found no evidence of increased risk of subsequent asthma diagnosis among children younger than 3 years of age who received LAIV compared with placebo.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000001783","type":"journal-article","created":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T23:45:30Z","timestamp":1505346330000},"page":"383-386","source":"Crossref","is-referenced-by-count":5,"title":["Live Attenuated Influenza Vaccination Before 3 Years of Age and Subsequent Development of Asthma"],"prefix":"10.1097","volume":"37","author":[{"given":"Roger P.","family":"Baxter","sequence":"first","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ned","family":"Lewis","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Fireman","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Hansen","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola P.","family":"Klein","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin R.","family":"Ortiz","sequence":"additional","affiliation":[{"name":"Initiative for Vaccine Research, World Health Organization, Geneva, Switzerland."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"suppl 1)","key":"R1-20230912","doi-asserted-by":"crossref","first-page":"A2","DOI":"10.1016\/j.vaccine.2011.02.079","article-title":"WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer.","volume":"29","author":"Friede","year":"2011","journal-title":"Vaccine"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6505a1","article-title":"Prevention and control of seasonal influenza with vaccines.","volume":"65","author":"Grohskopf","year":"2016","journal-title":"MMWR Recomm Rep"},{"issue":"suppl 4","key":"R4-20230912","doi-asserted-by":"crossref","first-page":"D10","DOI":"10.1016\/j.vaccine.2008.06.083","article-title":"Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age.","volume":"26","author":"Belshe","year":"2008","journal-title":"Vaccine"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/01.inf.0000109392.96411.4f","article-title":"Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents.","volume":"23","author":"Bergen","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S0140-6736(10)61380-3","article-title":"Role of viral respiratory infections in asthma and asthma exacerbations.","volume":"376","author":"Busse","year":"2010","journal-title":"Lancet"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1542\/peds.2004-2258","article-title":"Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial.","volume":"116","author":"Piedra","year":"2005","journal-title":"Pediatrics"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/infdis\/168.4.881","article-title":"Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia.","volume":"168","author":"Rudenko","year":"1993","journal-title":"J Infect Dis"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"e946","DOI":"10.1016\/S2214-109X(16)30200-5","article-title":"Efficacy of a Russian-backbone live attenuated influenza vaccine among young children in Bangladesh: a randomised, double-blind, placebo-controlled trial.","volume":"4","author":"Brooks","year":"2016","journal-title":"Lancet Glob Health"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1016\/j.vaccine.2015.04.048","article-title":"Safety of Russian-backbone seasonal trivalent, live-attenuated influenza vaccine in a phase II randomized placebo-controlled clinical trial among children in urban Bangladesh.","volume":"33","author":"Ortiz","year":"2015","journal-title":"Vaccine"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"e955","DOI":"10.1016\/S2214-109X(16)30201-7","article-title":"Efficacy of a Russian-backbone live attenuated influenza vaccine among children in Senegal: a randomised, double-blind, placebo-controlled trial.","volume":"4","author":"Victor","year":"2016","journal-title":"Lancet Glob Health"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/S0140-6736(11)61051-9","article-title":"Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis.","volume":"378","author":"Nair","year":"2011","journal-title":"Lancet"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1016\/j.vaccine.2016.07.045","article-title":"A global review of national influenza immunization policies: analysis of the 2014 WHO\/UNICEF Joint Reporting Form on immunization.","volume":"34","author":"Ortiz","year":"2016","journal-title":"Vaccine"},{"key":"R17-20230912","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2016.21.38.30350","article-title":"Decreased effectiveness of the influenza A(H1N1)pdm09 strain in live attenuated influenza vaccines: an observational bias or a technical challenge?","volume":"21","author":"Penttinen","year":"2016","journal-title":"Euro Surveil"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201805000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:34:59Z","timestamp":1694558099000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201805000-00003"}},"subtitle":["A 14-year Follow-up Study"],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001783","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}